Agoracom Blog Home

Posts Tagged ‘Marijuana’

Avicanna Inc. $AVCN.ca to Host Second Quarter 2020 Investor Conference Call $CRDL.ca $PCLO.ca $WEED.ca $ACB.ca

Posted by AGORACOM-JC at 6:46 PM on Friday, August 7th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

TORONTO, Aug. 7, 2020 – Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that it has scheduled a conference call on Monday, August 17, 2020 at 9:00AM Eastern Time to discuss the results for its fiscal second quarter ended June 30, 2020. Aras Azadian, Chief Executive Officer and Davender Sohi, Chief Financial Officer, will host the call and a question and answer period. The Company will report its financial results for the second quarter after the close of markets on Friday, August 14, 2020.

            Conference Call Details

DATE:                                           August 17, 2020                                   
TIME:  9:00 AM Eastern Time
  
CONFIRMATION #:                             64751998
  
TORONTO:                                           416-764-8659
NORTH AMERICAN TOLL FREE:         1-888-664-6392
GERMANY TOLL FREE:   08007240293
COLOMBIA TOLL FREE:      018005184036
  
REPLAY TORONTO:                             416-764-8677  
REPLAY NORTH AMERICA:    1-888-390-0541 
REPLAY ENTRY CODE:   751998#
REPLAY EXPIRATION DATE:               August 24, 2020

About Avicanna Inc.

Avicanna is an Ontario, Canada based corporation focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products through its two main business segments, cultivation and research and development.

Avicanna’s two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia are the base for Avicanna’s cultivation activities. These two companies are licensed to cultivate and process cannabis for the production of cannabis extracts and purified cannabinoids including cannabidiol (CBD) and tetrahydrocannabinol (THC).

Avicanna’s research and development business is primarily conducted out of Canada at its headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto. Avicanna’s scientific team develops products, and Avicanna has also engaged the services of researchers at the Leslie Dan Faculty of Pharmacy at the University of Toronto for the purpose of optimizing and improving upon its products.

Avicanna’s research and development and cultivation activities are focused on the development of its key products, including plant-derived cannabinoid pharmaceuticals, phyto-therapeutics, derma-cosmetics, and Extracts (defined as plant-derived cannabinoid extracts and purified cannabinoids, including distillates and isolates), with a goal of eventually having these products manufactured and distributed through various markets.

Stay Connected

For more information about Avicanna, visit www.avicanna.com, call 1-647-243-5283, or contact Setu Purohit, President by email at [email protected].

Cautionary Note Regarding Forward-Looking Information and Statements

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These forward-looking statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions, estimates and assumptions of management in light of management’s experience and perception of historical trends, current conditions and expected developments at the date the statements are made, such as current and future market conditions, the current and future regulatory environment and future approvals and permits. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements, including general business and economic conditions, changes in laws and regulations, product demand, changes in prices of required commodities, competition, the effects of and responses to the COVID-19 pandemic and other risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s annual information form dated April 15, 2020 (the “AIF“) and filed with Canadian securities regulators available on the Company’s issuer profile on SEDAR at www.sedar.com. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities laws.

SOURCE Avicanna Inc.

Are you an investor in Pharmacielo $PCLO.ca Check out our recent interview with Avicanna $AVCN.ca

Posted by AGORACOM-JC at 5:20 PM on Wednesday, August 5th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg
  • A Full Pipeline Of Pharmaceuticals In Various Stages Of Trials To Address Dermatology, Psychiatry, Neurology, Pain and Oncology
  • 3 Products Already As Far As PHASE 2

If you’re an investor in Aurora Cannabis $ACB Check out our recent interview with Avicanna $AVCN.ca

Posted by AGORACOM-JC at 5:25 PM on Tuesday, August 4th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

MEDICAL CANNABIS

  • Medical Cannabis 2.0 – Superior Products To Products Currently On The Market
    • Evidence Backed Medical Cannabis So Doctors Can Prescribe With Confidence
  • Launch Across Canada Immanent
  • Exclusive Distribution Through Online Store Of Shoppers Drug Mart
  • Global Distribution Through US, U.K, Australia, Colombia and Canada In H2 2020

If you’re an investor in Canopy Growth $WEED.ca Check out our recent interview with Avicanna $AVCN.ca

Posted by AGORACOM-JC at 4:44 PM on Friday, July 31st, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

CONSUMER RETAIL – COSMETICS

  • The Only Known CBD Cosmetics Backed By Clinical Trials
  • Full Line Of High End CBD Based Skin Care Products
  • Already Commercializing In Colombia
  • Global Distribution In H2 2020 In United States, Europe and Canada
    • Canadian Distribution Through Shoppers Drug Mart

VIDEO – Avicanna $AVCN.ca Is Delivering The Vertically Integrated #Cannabis Company That Others Failed To $WEED.ca $TLRY $HARV.ca

Posted by AGORACOM-JC at 4:50 PM on Thursday, July 30th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

The Tortoise and the Hare is the famous fable most of us grew up with that teaches this very important lesson – you can be more successful by doing things slowly and steadily than by acting quickly and carelessly.  Said another way, slow and steady wins the race.

Avicanna (AVCN:TSX) (AVCNF:OTCQB) (0NN:Frankfurt) is the Hare.  The company very few paid attention to because it started off the Cannabis stock market race slowly and surely, while all the other rabbits ran so quickly to win the race that they ended up tripping over themselves or getting so exhausted they couldn’t finish the race.

You know who those companies are.  All flash, big promises, big promotions, big stock prices ….. and HUGE disappointments.

Avicanna has surpassed all of them and is starting to pick up speed.  When Avicanna says it is vertically integrated, it isn’t a buzz word, it’s the real story with 4 fully operating divisions that are hitting on all cylinders including, Tier-1 National Partnerships, Global Distribution, Medical Acceptance and History Making Sales.

Here is a snapshot of what we are referring to, followed by an incredible interview with CEO, Aras Azadian, whose quiet confidence sends the following powerful message – 

“Watch Us Cross The Finish Line”

CONSUMER RETAIL – COSMETICS

  • The Only Known CBD Cosmetics Backed By Clinical Trials
  • Full Line Of High End CBD Based Skin Care Products
  • Already Commercializing In Colombia
  • Global Distribution In H2 2020 In United States, Europe and Canada
    • Canadian Distribution Through Shoppers Drug Mart

MEDICAL CANNABIS

  • Medical Cannabis 2.0 – Superior Products To Products Currently On The Market
    • Evidence Backed Medical Cannabis So Doctors Can Prescribe With Confidence
  • Launch Across Canada Immanent
  • Exclusive Distribution Through Online Store Of Shoppers Drug Mart
  • Global Distribution Through US, U.K, Australia, Colombia and Canada In H2 2020

     PHARMACEUTICALS

  • A Full Pipeline Of Pharmaceuticals In Various Stages Of Trials To Address Dermatology, Psychiatry, Neurology, Pain and Oncology
  • 3 Products Already As Far As PHASE 2

   CULTIVATION

  • 500,000 Sq Ft Of Low Cost and USDA certified Organic Cannabis Cultivation In Colombia
  • First Ever Export Of Feminized Hemp Seeds From Colombia (To United States). 7,000,000 Seeds For $380,000
  • Additional 75,000,000 Seeds Available For Export In Several Pending Transactions 

Watch this interview or listen by Podcast on AppleGoogleSpotify or your favourite podcaster.

Spyder Cannabis $SPDR.ca Announces Final Approvals to Open Niagara Falls and Calgary Cannabis Dispensaries $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 8:40 AM on Wednesday, July 29th, 2020
  • Announced that its dispensary located at 6474 Lundy’s Lane, passed its final inspection on July 27, 2020, and intends to open for business in the first week of August 2020
  • Also announced that its dispensary located at #140, 104 – 58 Avenue SE, was formally issued a Retail Cannabis Store License (No. 781144-1) and intends to open for business in August 2020

Vaughan, Ontario–(July 29, 2020) – Spyder Cannabis Inc. (TSXV: SPDR) (“Spyder” or the “Company“) and its wholly-owned associated applicants, The Green Spyder Inc. and Spyder Cannabis Subco Inc., is pleased to provide the following update:

Niagara Falls and Cannabis Dispensary

The Company is pleased to announce that its dispensary located at 6474 Lundy’s Lane, passed its final inspection on July 27, 2020, and intends to open for business in the first week of August 2020.

Calgary Cannabis Dispensary

The Company is also pleased to announce that its dispensary located at #140, 104 – 58 Avenue SE, was formally issued a Retail Cannabis Store License (No. 781144-1) and intends to open for business in August 2020.

“Both dispensaries are located in busy commercial hubs, in their respective cities. The Spyder team is excited to commence operations and bring its best of class customer service and retail experience to both cities”, stated Dan Pelchovitz, the Company’s CEO.

About Spyder Cannabis Inc.

Spyder is a Cannabis, Vape and CBD retailer that operates in jurisdictions where the products are federally legal in both Canada and the United States. The Company, through its subsidiaries, is a retailer involved in the development of three retail business units. The first is the sale of Cannabis products, the second is the sale of Hemp CBD in the United States only, the third is the sale of smoking cessation products in Ontario.

Cautionary Statements

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release includes statements containing certain ‘forward-looking information” within the meaning of applicable securities laws (‘forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur.

For additional info, please contact:

Spyder Cannabis Inc.
Dan Pelchovitz
President & Chief Executive Officer
Telephone: 1.888.504.7737
Email: [email protected]

TransCanna’s $TCAN.ca First Commercial Batch of World Class Cannabis Concentrates in Collaboration with the Summit Boys Available in Stores This Week $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 7:11 AM on Tuesday, July 28th, 2020
tcan-square

  • First batch of its cannabis concentrate products that is being co-branded with award-winning product producer, the Summit Boys, will be available for purchase this week
  • Lyfted Farms Inc. (a TransCanna subsidiary) is now supplying high-quality-cannabis ‘trim’ (a by-product of cannabis flower production) to the Summit Boys for processing into an already popular line of cannabis concentrates branded as ‘Caviar’

Vancouver, British Columbia–(July 28, 2020) – TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (“TransCanna” or the “Company”) TransCanna announces that the first batch of its cannabis concentrate products that is being co-branded with award-winning product producer, the Summit Boys, will be available for purchase this week.

Lyfted Farms Inc. (a TransCanna subsidiary) is now supplying high-quality-cannabis ‘trim’ (a by-product of cannabis flower production) to the Summit Boys for processing into an already popular line of cannabis concentrates branded as ‘Caviar.’ These retail products now also include innovative packaging featuring a ‘window’ to showcase the superior color and texture of the concentrates.

Cannabis concentrates have a greater proportion of cannabinoids and terpenes when compared to natural cannabis flowers, and can increase the potency of cannabis flower. Demand for these concentrates are also the fastest-growing of any cannabis product in the California market (the largest Cannabis market globally.)

The Summit Boys are a well-known legacy recreational cannabis product producer with a cult-like following on Instagram of over 66,000 followers. In 2019, the Summit Boys earned over 14 Bay Area Cannabis Cup awards in several categories, including for Best Product and Hybrid Concentrate.

“The sale of these products is the first exciting step in our distribution plan to bring a higher-quality product to market by aligning with California’s most reputable industry partners, said Bob Blink, TransCanna CEO, adding that consumers recognize the Summit Boys for their quality of product and processing superiority. This collaboration also increases our profit margin for each harvest by converting trim, which can be valued as low as USD $0.15 per gram, into a refined finished product that wholesales for USD $17.00 per gram.”

“Our goal has always been to make the best tasting and smelling products that drive customers to come back for what we have to offer. Now that we are using even higher quality trim from Lyfted Farms we can’t wait to see how our customers react,” said Mike Larson, the Summit Boys CEO. “This is the best product that we’ve ever produced. Fire into the process equals fire out.”

About TransCanna Holdings Inc.

TransCanna Holdings Inc. is a California based, Canadian listed Company building cannabis-focused brands for the California lifestyle through its wholly-owned California subsidiaries.

For further information, please visit the Company’s website at www.transcanna.com or email the Company at [email protected].

On behalf of the Board of Directors
Bob Blink, CEO
604-349-3011

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs regarding future events of management of the Company. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. This information and these statements referred to herein as “forward-looking statements”, are not historical facts, are made as of the date of this news release and include without limitation estimates and forecasts and statements as to management’s expectations for growth and the commencement of operations of the Company’s Daly facility.

The forward-looking information in this press release is based upon certain assumptions that management considers reasonable in the circumstances, including that operations will commence at the Company’s Daly facility in Modesto, California, as and when expected.

These forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially from any future results, events or developments expressed or implied by such forward-looking statements. Risks and uncertainties associated with the forward-looking information in this news release include, among others, dependence on obtaining and maintaining regulatory approvals, including state, local or other licenses and any inability to obtain all necessary governmental approvals licenses and permits to complete upgrades to its Daly facility in a timely manner; engaging in activities which currently are illegal under U.S. federal law and the uncertainty of existing protection from U.S. federal or other prosecution; regulatory or political change such as changes in applicable laws and regulations, including U.S. state-law legalization, particularly in California, due to inconsistent public opinion, perception of the medical-use and adult-use marijuana industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; reliance on management; and the effect of capital market conditions and other factors (including those related to the COVID-19 pandemic) on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with customers and suppliers.

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look, except in accordance with applicable securities laws.

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN

Avicanna $AVCN.ca announces the award of two Canadian government NSERC grants: 1) Cannabinoid-based pharmaceutical formulations for the treatment of COVID-19 in collaboration with the University of Toronto; and, 2) Evaluation of cannabinoids for reversing cannabis-based toxicosis in collaboration with the University of Guelph $CRDL.ca $PCLO.ca

Posted by AGORACOM-JC at 8:00 AM on Friday, July 24th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

In addition to a recent MITACS award, Dr. Christine Allen, a Professor at the University of Toronto, was awarded an NSERC Alliance grant for development of cannabinoid-based pharmaceutical formulations for the treatment of COVID-19 induced lung inflammation

Avicanna further expands its existing neurobiological research collaboration with Dr. Jibran Khokhar, a Professor at the University of Guelph, with a 2-year NSERC Alliance grant to investigate the neural basis of cannabis-induced toxicosis

The two NSERC grants leverage the proven track record of Avicanna, the University of Toronto and the University of Guelph in the research and clinical development of cannabinoid-based medicines

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/

TORONTO, July 24, 2020 – Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that the Company’s research collaborators have received two independent peer-reviewed grants from the Natural Sciences and Engineering Research Council of Canada (“NSERC“). The NSERC Alliance grants will be used to expand the investigators’ collaborative research with Avicanna.

For the past three years, Dr. Christine Allen’s research group (CARG) in the Leslie Dan Faculty of Pharmacy at the University of Toronto has supported the development and optimization of Avicanna’s cannabinoid-based products including commercial cosmetics (Pura H&W) and medical cannabis (Rho Phyto) product lines and the pharmaceutical pipeline that is currently under clinical investigation.  Dr. Allen will now leverage a recent MITACS award in addition to this NSERC Alliance grant in collaboration with Avicanna to develop a cannabinoid-based formulation for treatment of COVID-19 related lung inflammation.

A second NSERC Alliance grant was awarded to Dr. Jibran Khokhar, Assistant Professor at the University of Guelph, who has an extensive track-record in behavioural pharmacology and neuroscience. Avicanna’s research program with Dr. Khokhar focuses on evaluating a variety of cannabinoids in several preclinical models of human psychiatric conditions including mental health disorders such as anxiety, depression, and PTSD. The NSERC grant was awarded to evaluate the neurobiological underpinnings of cannabis toxicosis in a preclinical model, and test the potential efficacy of Avicanna’s naturally-derived cannabinoids and formulations in the treatment of cannabis-induced toxicosis. With the recent changes in the Canadian regulations for Cannabis 2.0 allowing for cannabinoid edibles and vapes, there is concern around an increased risk for adverse events arising from accidental high-dose cannabis ingestion. Thus, this two-year project will determine the behavioural and neural correlations of cannabis-induced toxicosis and the effects of cannabinoids for counteracting cannabis-induced toxicosis.

Dr Jibran Khokhar, commented, “This research is extremely timely with the new Cannabis 2.0 regulations and the increased risk for cannabis-induced toxicosis. I am thankful to NSERC and Avicanna for support of this important research that will have an impact in our understanding of the neurobiological underpinnings of, and provide novel treatment avenues to treat, adverse events related to high-dose cannabis exposures.”

About Avicanna Inc.

Avicanna is an Ontario, Canada based corporation focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products through its two main business segments, cultivation and research and development.

Avicanna’s two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia are the base for Avicanna’s cultivation activities. These two companies are licensed to cultivate and process cannabis for the production of cannabis extracts and purified cannabinoids including cannabidiol (CBD) and tetrahydrocannabinol (THC).

Avicanna’s research and development business is primarily conducted out of Canada at its headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto. Avicanna’s scientific team develops products, and Avicanna has also engaged the services of researchers at the Leslie Dan Faculty of Pharmacy at the University of Toronto for the purpose of optimizing and improving upon its products.

Avicanna’s research and development and cultivation activities are focused on the development of its key products, including plant-derived cannabinoid pharmaceuticals, phyto-therapeutics, derma-cosmetics, and Extracts (defined as plant-derived cannabinoid extracts and purified cannabinoids, including distillates and isolates), with a goal of eventually having these products manufactured and distributed through various markets.

Stay Connected

For more information about Avicanna, visit www.avicanna.com, call 1-647-243-5283, or contact Setu Purohit, President by email [email protected].

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, and includes statements with respect to the ability of the Company and CARG to develop cannabinoid-based pharmaceutical formulations to treat COVID-19 induced lung inflammation, the ability of the Company to develop cannabinoid-based pharmaceutical products, the results of the two-year project with the University of Guelph determining the behavioural and neural correlations of cannabis-induced toxicosis and the effect of cannabinoids to counteract cannabis-induced toxicosis. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated April 15, 2020, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com.

The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

SOURCE Avicanna Inc.

TransCanna $TCAN.ca Seizes New Processing Opportunity and Expands Operations at Daly Street Building $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 4:15 PM on Wednesday, July 22nd, 2020
tcan-square
  • Announced that Lyfted Farms Inc. (a wholly-owned subsidiary) will build a processing division inside its Daly Street Building
  • Aas not originally planned in phase one in order to meet the increased demand for this service and ultimately increase profits margins
  • Once operational, the division will oversee the trimming, drying, curing, grading and packaging of cannabis, and support TransCanna’s strategy of vertical integration of the California cannabis market through distribution centers serving Northern California from the Daly Street building, and Southern California from the Company’s recently announced Lemoore facility

Vancouver, British Columbia–(July 22, 2020) – TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (“TransCanna” or the “Company”) TransCanna announces that Lyfted Farms Inc. (a wholly-owned subsidiary) will build a processing division inside its Daly Street Building that was not originally planned in phase one in order to meet the increased demand for this service and ultimately increase profits margins.

Once operational, the division will oversee the trimming, drying, curing, grading and packaging of cannabis, and support TransCanna’s strategy of vertical integration of the California cannabis market through distribution centers serving Northern California from the Daly Street building, and Southern California from the Company’s recently announced Lemoore facility.

“Once we received our final State License for the Daly Building, our already existing demand increased significantly. To meet this demand and seize the opportunity we saw to really drive our bottom line margin through processing, we sped up the timeline to add processing at this level,” said Bob Blink, TransCanna CEO. “We have the team and the space to execute this. Being agile enough to adapt to a changing market and identify opportunities for growth within it speaks to our collective mindset. When we run the numbers, we can see upon execution this service adding an additional 10% to our forecasted revenue targets,” adds Blink.

“This will facilitate the larger strategy of the Daly facility becoming a central distribution point for Lyfted Branded products and a wholesale processing center,” said Alan Applonie, company General Manager. “Converging marketing and buying interests into a single Northern California location gives state-wide buyers a broader range of products to purchase,” he adds.

The Processor License is an additional license type not included in the original statute specifically added for processors. As this is a new business segment whilst being built out, the Company has submitted an application for a Processor License and anticipates approximately a 90-day timeline to receive it.

The Daly building’s phase one deployment plan will also accommodate perpetual storage of at least 20,000 lbs. of cannabis flower in a climate-controlled atmosphere that will serve business-to-business cannabis market demand throughout California.

About TransCanna Holdings Inc.

TransCanna Holdings Inc. is a California based, Canadian listed, Company building cannabis-focused brands for the California lifestyle, through its wholly-owned California subsidiaries.

For further information, please visit the Company’s website at www.transcanna.com or email the Company at [email protected].

On behalf of the Board of Directors
Bob Blink, CEO
604-349-3011

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs regarding future events of management of the Company. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. This information and these statements referred to herein as “forward-looking statements”, are not historical facts, are made as of the date of this news release and include without limitation estimates and forecasts and statements as to management’s expectations for growth and the commencement of operations of the Company’s Daly facility.

The forward-looking information in this press release is based upon certain assumptions that management considers reasonable in the circumstances, including that operations will commence at the Company’s Daly facility in Modesto, California, as and when expected.

These forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially from any future results, events or developments expressed or implied by such forward-looking statements. Risks and uncertainties associated with the forward-looking information in this news release include, among others, dependence on obtaining and maintaining regulatory approvals, including state, local or other licenses and any inability to obtain all necessary governmental approvals licenses and permits to complete upgrades to its Daly facility in a timely manner; engaging in activities which currently are illegal under U.S. federal law and the uncertainty of existing protection from U.S. federal or other prosecution; regulatory or political change such as changes in applicable laws and regulations, including U.S. state-law legalization, particularly in California, due to inconsistent public opinion, perception of the medical-use and adult-use marijuana industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth;; reliance on management; and the effect of capital market conditions and other factors (including those related to the COVID-19 pandemic) on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with customers and suppliers.

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look, except in accordance with applicable securities laws.

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN

TransCanna $TCAN.ca and Award-Winning Product Producers, the Summit Boys, to Co-Brand #Cannabis Concentrates $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 7:11 AM on Tuesday, July 21st, 2020
tcan-square
  • Announced a Memorandum of Understanding with award-winning and leading legacy cannabis brand, the Summit Boys, to co-brand a series of high-quality cannabis concentrates
  • Summit Boys are a well-known legacy recreational cannabis product producers (operating since 2016 under prop 215 and with a cult-like following on Instagram of over 66,000 followers).
  • Demand for Cannabis Concentrates are the Fastest Growing of all Related Product Categories

Vancouver, British Columbia–(July 21, 2020) – TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (“TransCanna” or the “Company”) is pleased to announce a Memorandum of Understanding with award-winning and leading legacy cannabis brand, the Summit Boys, to co-brand a series of high-quality cannabis concentrates.

The Summit Boys are a well-known legacy recreational cannabis product producers (operating since 2016 under prop 215 and with a cult-like following on Instagram of over 66,000 followers). In this agreement, Lyfted Farms (a TransCanna subsidiary), will supply high-quality cannabis flower to the Summit Boys for processing into a line of popular cannabis concentrates branded as ‘Caviar.’

In 2019, the Summit Boys earned 14 awards in the Bay Area Cannabis Cup in several categories, including for Best Product and Hybrid Concentrate for this same Caviar product. The line of ‘White Caviar’ branded products are what The Summit Boys are best known for.

Cannabis concentrates have a greater proportion of cannabinoids and terpenes when compared to natural cannabis flowers, and can increase the potency of cannabis flower. Demand for these concentrates are also the fastest-growing of any cannabis product in the California market (the largest Cannabis market globally).

“This co-branding of the already famous Caviar product now powered by Lyfted’s flower is great news for cannabis consumers,” says Bob Blink, TransCanna CEO. “For us, it’s another example of our strategy to align with high-quality producers and already successful players in the industry-this time with the added value of the Summit Boys’ grassroots following. But for the more sophisticated California cannabis market, this partnership will mean an even higher quality product for consumers.”

“As a dedicated brand to California Cannabis market, we wanted to find like-minded partners. Since meeting the Lyfted team, they have earned our respect, and we definitely look forward to working together. There are many things that excite us, but being able to co-brand and scale now that the Daly Facility is licensed is a huge opportunity, ” stated Mike Larson, Summit Boys CEO.

News of this agreement follows an announcement by TransCanna that the Company was awarded its final operating license for the 196,000 square foot Daly Facility by the California Bureau of Cannabis Control July 10, 2020.

About TransCanna Holdings Inc.

TransCanna Holdings Inc. is a California based, Canadian listed company building Cannabis-focused brands for the California lifestyle, through its wholly-owned California subsidiaries.

For further information, please visit the Company’s website at www.transcanna.com or email the Company at [email protected].

On behalf of the Board of Directors,

Bob Blink, CEO
604-349-3011

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs regarding future events of management of the Company. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. This information and these statements, referred to herein as “forward-looking statements”, are not historical facts, are made as of the date of this news release and include without limitation estimates and forecasts and statements as to management’s expectations for growth and the commencement of operations of the Company’s Daly facility.

The forward-looking information in this press release is based upon certain assumptions that management considers reasonable in the circumstances, including that operations will commence at the Company’s Daly facility in Modesto, California, as and when expected.

These forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially from any future results, events or developments expressed or implied by such forward-looking statements. Risks and uncertainties associated with the forward-looking information in this news release include, among others, dependence on obtaining and maintaining regulatory approvals, including state, local or other licenses and any inability to obtain all necessary governmental approvals licenses and permits to complete upgrades to its Daly facility in a timely manner; engaging in activities which currently are illegal under U.S. federal law and the uncertainty of existing protection from U.S. federal or other prosecution; regulatory or political change such as changes in applicable laws and regulations, including U.S. state-law legalization, particularly in California, due to inconsistent public opinion, perception of the medical-use and adult-use marijuana industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth;; reliance on management; and the effect of capital market conditions and other factors (including those related to the COVID-19 pandemic) on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with customers and suppliers.

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look, except in accordance with applicable securities laws.